XFOR

X4 Pharmaceuticals, Inc

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001501697 Biotech & Drug Discovery

$3.25 +0.01 (+0.31%)

Oct 26 4:00 PM ET · prev $3.24

Market cap

$317.3M

Small cap

Median target

$12.00

+269% · range $10.00–13.00

Next earnings

Nov 3

in 8 days · EPS est. −$0.19

1 year

−13.1%

from $3.74 · Oct 27

30 days

+7.8%

from $3.02

52-week range

$2.45–4.67

−30% from high · low Oct 14

Avg volume 20D

727.0K

shares / day

Short interest

🔒 Subscribers only

Insider net

−$451.1K

1 buyer · 3 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 7 reports · 90 days

Balance 0 bearish · 1 bullish · 1 mixed · 5 neutral oldest → newest, height = score

Avg score

·High conf. 7/7 ·Next Earnings date, Nov 3, 2026

Strongest MIXED X4 Pharmaceuticals entered into a $150M senior secured term loan facility with K2 HealthVentures, receiving…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S May 12 1 insider sell $72.8K at $4.29
S Jun 30 1 insider sell $36.4K at $4.26
A Jul 10 Wells Fargo initiates
S Aug 12 2 insiders sell $320.1K at $4.44
R Sep 8 X4 Pharmaceuticals announced a positive FDA Type C meeting outcome f…
S Oct 1 1 insider sell $33.7K at $2.86
R Oct 8 X4 Pharmaceuticals entered into a $150M senior secured term loan fac…
B Oct 16 1 insider buy $11.9K at $2.58

Signal stack

Where each data set points today.

InsidersBEARISH

1 insider bought $11.9K at an average $2.58. 3 insiders sold $463.0K. Price is 26% above their cost.
InstitutionsBULLISH

Q2 2026: 12 added (0 new), 3 trimmed or exited.
EstimatesRISING

Current-quarter EPS estimate −$0.192 → −$0.186 over 90 days. 1 up, 0 down in 30 days.
TrendDOWNTREND

4% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	DOUBLED	5,554,906	$25.9M
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	2,098,047	$9.8M
STATE STREET CORP	DOUBLED	1,296,017	$6.1M
NORTHERN TRUST CORP	DOUBLED	652,849	$3.0M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	DOUBLED	263,264	$1.2M
CITIGROUP INC	ADD	70,112	$327.4K
UBS Group AG	NEAR_EXIT	58,043	$271.1K
BANK OF AMERICA CORP /DE/	TRIM	46,861	$218.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026

12-month targets · 5 analysts

$3.25 $10.00 $12.00 $13.00

Price is below the lowest target. Median implies +269%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Jul 10, 2026	Wells Fargo INITIATE	INITIATE	Overweight
Jun 2, 2026	Leerink Partners INITIATE	INITIATE	Outperform

Insider ledger

Form 4

$11.9K

bought · 1 insider

$463.0K

sold · 3 insiders

+25.8%

vs their $2.58 cost

Date	Insider	Type	Value
Oct 16, 2026	Craig Adam R Executive Chairman	BUY	$11.9K
Oct 1, 2026	KIRSKE DAVID Chief Financial Officer	SELL	$33.7K
Aug 12, 2026	Volpone John President	SELL	$109.2K
Aug 12, 2026	Craig Adam R Executive Chairman	SELL	$210.8K
Jul 1, 2026	Gold Kelly Director	AWARD	110,000 sh
Jun 30, 2026	KIRSKE DAVID Chief Financial Officer	SELL	$36.4K
May 12, 2026	KIRSKE DAVID Chief Financial Officer	SELL	$72.8K

Earnings setup

Estimates

Nov 3

reports in 8 days

−$0.19

EPS estimate, this quarter

+3%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.192

90d

−$0.186

60d

−$0.186

30d

−$0.186

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.19	-$0.22–-$0.16	+0.0%	$2.3M
Next Q	-$0.20	-$0.28–-$0.16	+0.0%	$2.3M
Current FY	-$0.67	-$0.79–-$0.59	+0.0%	$16.0M
Next FY	-$0.77	-$1.00–-$0.65	+0.0%	$11.6M